Research programme: topical NSAID - Milestone Pharmaceuticals
Latest Information Update: 01 Apr 2011
At a glance
- Originator Milestone Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis; Exanthema; Osteoarthritis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 09 Aug 2007 Preclinical trials in Actinic keratosis in Canada (Topical)
- 09 Aug 2007 Preclinical trials in Exanthema in Canada (Topical)
- 09 Aug 2007 Preclinical trials in Osteoarthritis in Canada (Topical)